Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

Key: what the circles and colors mean

Each circle is a bill. The ring fills as it moves through Congress:

IntroducedPassed one chamberPassed both chambersBecame law (gold)Resolution agreed to (full, dark)Failed or vetoed (gray)

Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.

Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.

Never voted on. It didn't reach a floor vote before the 118th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.

R SchweikertSponsor

35 cosponsors · 14 D, 21 R

13 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

What it does: CRS summary · Introduced in House · Nov 3, 2023

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.

Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov

About this bill and sources

Official title: Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

Latest action (Nov 10, 2023): Referred to the Subcommittee on Health.

Policy area: Health · Origin: House · Introduced: Nov 3, 2023

Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)

No recorded floor vote found.